Business report :
Libra Infusions Limited published its three-quarters financial statement from the July to March period of FY22, whereas the company posted impressive profit growth compared to the previous FY.
According to the stock exchange disclosure on Sunday, in FY22, in the July to March period, its earnings per share stood at Tk4, which was a loss of Tk6.44 in the same period of the previous fiscal year.
In the January to March quarter, its earnings per share stood at Tk1.37, which was a loss of Tk5.69 in the same period of the previous fiscal year.
In the October to December quarter, its earnings per share stood at Tk1.78, which was a loss of Tk1.48 in the same period of the previous fiscal year.
From July to September, its earnings per share stood at Tk0.85, which was Tk0.71 in the same period of the previous fiscal year.
End of March 2022, its net asset value per share was Tk843. Investors were left in the dark because the company failed to publish its financial disclosures in a timely and comprehensive manner. As a result, they were unable to make well-informed decisions regarding their investments in the company.
In August, its share price was Tk674, which reached Tk1063.8 within 14 working days. After September it also went down to Tk744 amid political and economic uncertainty.
On Sunday, the share price of the company stood at Tk957.5 on the Dhaka Stock Exchange.
Market insiders say the country’s largest saline producer, Libra Infusions, currently has a paid-up capital of only Tk2.25 crore, while the regulatory requirement is Tk30 crore.
The Bangladesh Securities and Exchange Commission had previously instructed the company to raise its paid-up capital to meet the regulatory standard.
Additionally, the company is set to launch the country’s largest dialysis fluid production plant, which could significantly enhance its profitability. Market insiders have also said that the company might take steps to increase its paid-up capital, with an announcement expected in the coming days.
